Arcutis Biotherapeutics Inc (NASDAQ:ARQT)’s traded shares stood at 1.35 million during the latest session, with the company’s beta value hitting 1.67. At the last check today, the stock’s price was $17.06, to imply an increase of 2.77% or $0.46 in intraday trading. The ARQT share’s 52-week high remains $17.70, putting it -3.75% down since that peak but still an impressive 59.03% since price per share fell to its 52-week low of $6.99. The company has a valuation of $2.02B, with an average of 2.77 million shares in intraday trading volume over the past 10 days and average of 2.33 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Arcutis Biotherapeutics Inc (ARQT), translating to a mean rating of 1.25. Of 3 analyst(s) looking at the stock, 1 analyst(s) give ARQT a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) trade information
After registering a 2.77% upside in the latest session, Arcutis Biotherapeutics Inc (ARQT) has traded red over the past five days. The 5-day price performance for the stock is 15.19%, and 31.33% over 30 days. With these gigs, the year-to-date price performance is 22.47%. Short interest in Arcutis Biotherapeutics Inc (NASDAQ:ARQT) saw shorts transact 19.77 million shares and set a 8.42 days time to cover.
The extremes give us $19 and $19 for target low and target high price respectively. As such, ARQT has been trading -11.37% off suggested target high and -11.37% from its likely low.
ARQT Dividends
Arcutis Biotherapeutics Inc has its next earnings report out on 2025-Feb-24. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT)’s Major holders
Arcutis Biotherapeutics Inc insiders hold 2.02% of total outstanding shares, with institutional holders owning 112.30% of the shares at 114.61% float percentage. In total, 112.30% institutions holds shares in the company, led by JENNISON ASSOCIATES LLC. As of 2024-06-30, the company held over 11.57 million shares (or 9.3712% of shares), all amounting to roughly $107.62 million.
The next major institution holding the largest number of shares is SUVRETTA CAPITAL MANAGEMENT, LLC with 10.0 million shares, or about 8.1021% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $93.04 million.
We also have Vanguard Total Stock Market Index Fund and PGIM JENNISON SMALL COMPANY FUND as the top two Mutual Funds with the largest holdings of the Arcutis Biotherapeutics Inc (ARQT) shares. Going by data provided on Dec 31, 2024 , Vanguard Total Stock Market Index Fund holds roughly 3.23 shares. This is just over 2.72% of the total shares, with a market valuation of $55.78 million. Data from the same date shows that the other fund manager holds a little less at 3.09, or 2.60% of the shares, all valued at about 53.31 million.
